ZIG
AVIR icon

Zullo Investment Group’s Atea Pharmaceuticals AVIR Stock Holding History

Zullo Investment Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-500
Closed -$2.4K – 172
2022
Q4 		$2.4K Hold
500
– – ﹤0.01% 674
2022
Q3 		$3K Hold
500
– – ﹤0.01% 642
2022
Q2 		$4K Hold
500
– – ﹤0.01% 643
2022
Q1 		$4K Hold
500
– – ﹤0.01% 673
2021
Q4 		$4K Buy
+500
New +$7.79K ﹤0.01% 678

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zullo Investment Group's AVIR Position: Q1 2023 in Review

Zullo Investment Group sold out of Atea Pharmaceuticals (AVIR) in Q1 2023, closing a stake of 500 shares — an estimated $2.4K sold.

Zullo Investment Group first reported a position in AVIR in Q4 2021 and held it in 5 quarters. The position peaked at $4K in Q2 2022. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

  • Zullo Investment Group reported no remaining Atea Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Zullo Investment Group sold 500 Atea Pharmaceuticals shares in Q1 2023, an estimated $2.4K.
  • Zullo Investment Group first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Zullo Investment Group's Atea Pharmaceuticals position peaked at $4K in Q2 2022.
  • 130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on Zullo Investment Group's 13F filing for Q1 2023, filed 25 Apr 2023.